Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Bought by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC grew its position in Inozyme Pharma, Inc. (NASDAQ:INZY) by 155.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,000 shares of the company’s stock after buying an additional 31,000 shares during the quarter. OneDigital Investment Advisors LLC owned 0.08% of Inozyme Pharma worth $141,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Jane Street Group LLC boosted its position in Inozyme Pharma by 7.5% in the 3rd quarter. Jane Street Group LLC now owns 49,460 shares of the company’s stock valued at $259,000 after buying an additional 3,443 shares during the period. JPMorgan Chase & Co. grew its stake in Inozyme Pharma by 31.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company’s stock worth $151,000 after purchasing an additional 6,851 shares in the last quarter. Palumbo Wealth Management LLC increased its holdings in Inozyme Pharma by 52.3% during the 4th quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company’s stock worth $64,000 after purchasing an additional 7,995 shares during the period. American Century Companies Inc. raised its position in Inozyme Pharma by 11.6% in the 4th quarter. American Century Companies Inc. now owns 79,349 shares of the company’s stock valued at $220,000 after purchasing an additional 8,263 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Inozyme Pharma by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,179,622 shares of the company’s stock valued at $3,268,000 after buying an additional 8,450 shares during the period. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Wells Fargo & Company reduced their target price on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price objective on shares of Inozyme Pharma in a research report on Tuesday, April 8th. Piper Sandler lowered their target price on shares of Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th. Wedbush restated an “outperform” rating and issued a $7.00 price target (down from $12.00) on shares of Inozyme Pharma in a research note on Monday, March 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Inozyme Pharma in a research report on Thursday, April 10th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $14.63.

Inozyme Pharma Stock Performance

Shares of INZY stock opened at $1.06 on Wednesday. Inozyme Pharma, Inc. has a 1 year low of $0.72 and a 1 year high of $6.24. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. The firm has a market cap of $68.09 million, a price-to-earnings ratio of -0.68 and a beta of 1.39. The stock’s 50-day moving average is $1.01 and its two-hundred day moving average is $2.19.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.